Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse.
Våre nettsider benytter cookies. Dersom cookien ikke er nødvendig for at nettsiden vår skal fungere,
vil den ikke lagres på din enhet med mindre du samtykker til dette.
Les mer om cookies her.
Ikke satt ennå.
Prof. Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. As leading researcher in multiple myeloma, Prof. Moreau is head of the unit for early phase 1 and phase 2 trials in clinical hematology at the University Hospital of Nantes. Prof. Moreau is currently a member of the administration council f the Intergroupe Francophone du Myélome (IFM), and he was chairman of the IFM from 2006 through 2009. Prof. Moreau is widely published, with more than 240 per-reviewed articles and reviews that have appeared in high impact factor journals including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Blood.
Prof. Torben Plesner, MD, is a world-renowned myeloma expert and currently practices hematology at Vejle Hospital in Denmark and is a Professor at the University of Southern Denmark. Prof. Plesner was involved in the earliest work on daratumumab. He has been leading clinical trials and have several peer-reviewed articles published in impact journals.
Fredrik Schjesvold, MD, PhD, is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. He earned his medical degree from the University of Oslo in 2001. He has previously headed the units of hematology at Diakonhjemmet hospital and Bærum hospital in Norway.
Dr. Schjesvold is an international expert on Multiple Myeloma, with one of Europe’s largest centers for clinical research in this disease. This includes being the national coordinator of 30 clinical myeloma trials, and in addition being the principal investigator of 3 large myeloma studies. He is also an expert on light chain amyloidosis.